

Mutations of the Mitochondrial-tRNA Modifier *MTO1* Cause Hypertrophic Cardiomyopathy and Lactic Acidosis

Daniele Ghezzi,^{1,7} Enrico Baruffini,^{2,7} Tobias B. Haack,^{3,4} Federica Invernizzi,¹ Laura Melchionda,¹ Cristina Dallabona,² Tim M. Strom,^{3,4} Rossella Parini,⁵ Alberto B. Burlina,⁶ Thomas Meitinger,^{3,4} Holger Prokisch,^{3,4} Ileana Ferrero,² and Massimo Zeviani^{1,*}

Dysfunction of mitochondrial respiration is an increasingly recognized cause of isolated hypertrophic cardiomyopathy. To gain insight into the genetic origin of this condition, we used next-generation exome sequencing to identify mutations in *MTO1*, which encodes mitochondrial translation optimization 1. Two affected siblings carried a maternal c.1858dup (p.Arg620Lysfs*8) frameshift and a paternal c.1282G>A (p.Ala428Thr) missense mutation. A third unrelated individual was homozygous for the latter change. In both humans and yeast, *MTO1* increases the accuracy and efficiency of mtDNA translation by catalyzing the 5-carboxymethylaminomethylation of the wobble uridine base in three mitochondrial tRNAs (mt-tRNAs). Accordingly, mutant muscle and fibroblasts showed variably combined reduction in mtDNA-dependent respiratory chain activities. Reduced respiration in mutant cells was corrected by expressing a wild-type *MTO1* cDNA. Conversely, defective respiration of a yeast *mto1Δ* strain failed to be corrected by an Mto1^{Pro622*} variant, equivalent to human MTO1^{Arg620Lysfs*8}, whereas incomplete correction was achieved by an Mto1^{Ala431Thr} variant, corresponding to human MTO1^{Ala428Thr}. The respiratory yeast phenotype was dramatically worsened in stress conditions and in the presence of a paromycin-resistant (P^R) mitochondrial rRNA mutation. Lastly, in vivo mtDNA translation was impaired in the mutant yeast strains.

Infantile hypertrophic cardiomyopathy and lactic acidosis are key clinical features in an increasing number of mitochondrial disorders associated with severe dysfunction of oxidative phosphorylation (OXPHOS), the main energy-supply pathway of cardiomyocytes. The advent of exome analysis by next-generation sequencing (NGS) technology has begun to elucidate the genetic defects underpinning this condition. Recently, exome-NGS allowed us to identify mutations in *ACAD9* (MIM 611103), which encodes mitochondrial flavin adenine dinucleotide (FAD)-dependent acyl-coenzyme-A dehydrogenase 9, in several children affected by early-onset, isolated hypertrophic cardiomyopathy (MIM 611126).¹ The role of *ACAD9* seems to be marginal for fatty-acid beta oxidation, but essential for the assembly of mitochondrial respiratory chain (MRC) complex I (CI).^{1–3} Another recent example is mutations in *AGK* (MIM 610345), which encodes acyl-glycerol kinase, a mitochondrial enzyme involved in the biosynthesis of cardiolipin; these mutations are responsible for hypertrophic cardiomyopathy and congenital cataracts (Sengers syndrome [MIM 212350]).⁴ Cardiolipin is an essential component of the lipid milieu of the inner mitochondrial membrane that participates in the integrity and optimization of the activity of both the MRC complexes and the skeletal-muscle- and heart-specific solute carrier family 25 (adenine nucleotide translocator 1), *SLC25A4*. Likewise, rare, recessive mutations in *SLC25A4* (MIM 103220) also cause hypertrophic cardio-

myopathy (MIM 192600), and yet another X-linked recessive condition, Barth syndrome, hallmarked by severe mitochondrial cardiomyopathy (MIM 302060), is caused by a mutation in *TAZ* (MIM 300394), which encodes Tafazzin, an acyl-transferase, specific to cardiolipin, that optimizes its fatty-acid composition to the structural and functional needs of the MRC. Other children with severe, isolated cardiomyopathy and lactic acidosis harbor recessive mutations in *TMEM70* (MIM 612418), which encodes a bona fide assembly factor of MRC CV (ATP-synthase).⁵ Syndromic cardiomyopathy, in combination with encephalopathy, myopathy, or both, is also associated with a number of mutations of mtDNA or nuclear genes that affect MRC activities.⁶ Nevertheless, a substantial proportion of cases characterized by OXPHOS-related severe hypertrophic cardiomyopathy remains genetically undiagnosed.

Through exome-NGS analysis of a selected cohort of affected individuals, we identified pathogenic mutations in *MTO1* (NC_000006.11), which encodes an enzyme involved in posttranscriptional modification of mitochondrial tRNAs (mt-tRNAs).

Affected person 1 (Pt1) was the first child of nonconsanguineous, healthy parents from northern Italy. He was born at 29 weeks of gestational age, by caesarean section because of oligohydramnios and reduced fetal growth. His birth weight was 790 g, his length was 34.5 cm, and his head circumference was 25.5 cm. Immediately after

¹Unit of Molecular Neurogenetics, Fondazione IRCCS (Istituto di Ricovero e Cura a Carattere Scientifico) Istituto Neurologico “Carlo Besta,” 20126 Milan, Italy; ²Department of Genetics, Biology of Microorganisms, Anthropology, and Evolution, University of Parma, 43124 Parma, Italy; ³Institute of Human Genetics, Helmholtz Zentrum München, 85764 Neuherberg, Germany; ⁴Institute of Human Genetics, Technische Universität München, 80333 Munich, Germany; ⁵Rare Metabolic Diseases Unit, Pediatric Clinic, San Gerardo Hospital, University of Milano-Bicocca, 20090 Monza, Italy; ⁶Metabolic Diseases Unit, Department of Paediatrics, University of Padua School of Medicine, 35128 Padua, Italy

⁷These authors contributed equally to this work

*Correspondence: zeviani@istituto-besta.it

DOI 10.1016/j.ajhg.2012.04.011. ©2012 by The American Society of Human Genetics. Open access under [CC BY-NC-ND license](http://creativecommons.org/licenses/by-nc-nd/4.0/).

Table 1. Biochemical Analysis of OXPHOS Activities

Muscle	CS ^a	CI	SDH	CII	CIII	CIV	CV
Ct values	80–210	13–24	10.7–17.4	15–28	60–100	120–220	130–280
Pt2	73	5 (27)	16.8 (120)	28.7 (133)	95.3 (119)	46.5 (27)	351 (171)
Pt3 (3 mo)	209	2.2 (12)	13.1 (93)	nd ^b	nd ^b	51 (30)	nd
Pt3 (17 yr)	147	1.3 (7)	13.6 (97)	26.3 (122)	75 (94)	59 (35)	144 (70)
Fibroblasts	CS ^a	CI	SDH	CII	CIII	CIV	CV
Ct values	100–200	10.7–26	6.5–14.3	8.6–18.4	70–120	70–125	65–113
Pt1	160	12.5 (68)	14.3 (137)	24.6 (182)	57 (60)	55 (56)	93 (104)
Pt2	101	10.1 (55)	11 (105)	30.3 (224)	92 (97)	111 (114)	126 (141)
Pt1 + riboflavin	142	11.6 (63)	nd	nd	53 (56)	62 (64)	nd
Pt2 + riboflavin	82	6.5 (35)	nd	nd	71 (75)	76 (78)	nd

nd, not determined; + riboflavin, fibroblasts cultured for 1 week with Dulbecco's modified Eagle's medium (DMEM) supplemented with 5.3 μ M riboflavin. Parentheses indicate percentages relative to the mean control (Ct) value. Values below the control range are reported in bold. All enzymatic activities are normalized for CS activity. Two muscle biopsies were analyzed in Pt3; the first taken at 3 months of age (3 mo) and the second at 17 years of age (17 yr).

^aCitrate synthase (CS) activity, expressed as $\text{nmol min}^{-1} \text{mg}^{-1}$.

^bIn Pt3 muscle, the ratio CII+CIII (succinate cytochrome c reductase)/CS was 16.6 (105% of the Ct value; normal range 12.2–19.4).

birth he had an episode of metabolic failure with severe hypoglycemia (25 mg%), metabolic acidosis (pH 7.17, base excess [BE] -11.7 mEq/l), and high blood lactate (13 mM, normal values [nv] < 2.0). In the subsequent days, blood glucose levels were corrected by the infusion of dextrose, whereas plasma lactate remained high (10–15 mM), with mild hyperammonemia (195 μ g%, nv < 80). Electroencephalogram (EEG) and cerebral echography results were normal, as were those of a liver and spleen ultrasound examination. Interventricular septum hypertrophy was detected on the 15th day (6.4 mm, nv < 3). He died on the 19th day of sudden bradycardia unresponsive to resuscitation procedures. MRC activities in digitonin-permeabilized skin fibroblasts showed a reduction of CIII normalized to citrate synthase (CS) (CIII/CS = 60% of the controls' mean) and of CIV/CS (56%), whereas the other activities were within the controls' range (Table 1). Sequence analysis of muscle mtDNA revealed a normal H1t haplogroup common in Europeans.

Affected person 2 (Pt2), our index case, was the younger sister of Pt1. She also was born at 36 weeks of gestational age by caesarean section because of oligohydramnios and reduced fetal growth. Her birth weight was 1,380 g, her length was 42 cm, and her head circumference was 30 cm. At birth, she was mildly hypotonic and had severe metabolic acidosis (pH 7.21, BE -13 mEq/l), with high blood lactate (17.9 mM). She was immediately started on biotin (10 mg per day), Coenzyme Q10 (14 mg per day), thiamine (150 mg per day), and dichloroacetate (DCA; 30 mg per day). Plasma lactate stabilized to values between 6 and 10 mM. EEG and brain ultrasound results were normal. On the seventh day, she became tachycardic. Heart ultrasound findings were normal until the 38th day, when septum hypertrophy (7 mm, nv 3.5) and left-ventricular-wall hypertrophy (6 mm, nv 4) were found.

She died on the 40th day of sudden bradycardia unresponsive to resuscitation procedures. An autopsy showed the presence of cardiomegaly, pleural effusion, and ascites. Biochemical assays, performed on the 800 \times g supernatant from the homogenate of a muscle biopsy, showed a reduction of the ratios of CI/CS and CIV/CS. MRC activities in digitonin-permeabilized fibroblasts showed only the reduction of CI/CS (Table 1). Sequence analysis of muscle mtDNA revealed a normal H1t haplogroup, and Sanger sequence analysis of *ACAD9*, *TMEM70*, *NDUFS2* (MIM 602985), and *NDUFV2* (MIM 600532) showed no mutation.

Affected person 3 (Pt3), a boy, was born at term to reportedly nonconsanguineous, healthy parents originating from a small village in the alpine region of northeastern Italy. His initial clinical history has been reported elsewhere.⁷ At the age of 1 month, he developed hyperpnea, difficulty feeding, weakness, and a lack of ocular fixation. His liver was 5 cm below the costal margin; he had severe metabolic acidosis, with high blood lactate (5.5 mM, nv < 2.0). An electrocardiogram (ECG) showed signs of ischemia, and a cardiac ultrasound examination revealed marked hypertrophic cardiomyopathy, particularly affecting the posterior wall of the left ventricle (8.5 mm, nv 4), reduced left-ventricular function, and mild pericardial effusion. Biochemical assays on the 800 \times g supernatant of the homogenate from a muscle biopsy taken at 3 months of age revealed severe reduction of CI/CS (12% of the controls' mean) and CIV/CS (30%) ratios, whereas succinate dehydrogenase (SDH)/CS and CII+III/CS ratios as well as CS (Table 1) and pyruvate dehydrogenase activities were normal. DCA treatment resulted in marked improvement of both metabolic acidosis and cardiomyopathy. After 9 months of DCA therapy, a cardiac ultrasound examination showed a normal-sized heart, with normal

left-ventricular-wall thickness (5 mm) and function (ejection fraction 76%, systolic fraction 43%) and low blood lactate values, ranging from 1.6 to 3.1 mM. During his first years of life, Pt3 had no severe episode of metabolic acidosis, even if plasma lactate remained moderately high, ranging from 2.5 to 4 mM. His growth rate has been normal, with good neurological development and a normal brain anatomy, according to magnetic resonance imaging. He was put on a permanent treatment of DCA (200 mg per day), carnitine (1 g per day), and CoQ₁₀ (100 mg per day). Because of the possible side effects of DCA, he was monitored regularly through the evaluation of visual and brainstem auditory evoked potentials as well as electromyography and nerve conduction velocities. At the age of 7 years, ultrasound examination showed a normal systolic ejection fraction in spite of a slight dilation of the left-ventricular chamber. At 12 years, DCA was stopped because of normalization of plasma lactate. A second muscle biopsy, taken at 17 years, again showed severe reduction of CI/CS (7% of the controls' mean) and CIV/CS (35%), whereas the other MRC activities were normal (Table 1). Sequence analysis of mtDNA showed a normal H2 haplogroup. He is now 19 years old with a normal scholastic performance. A recent ultrasound examination revealed the presence of hypertrophic cardiomyopathy with an ejection fraction of 60%. An ECG showed sinus bradycardia (45 beats per min) but a Holter ECG was otherwise normal. A neurological examination was normal, except for a reduction of skills in the execution of fine movements, more evident in the left hand. Ophthalmoscopic examination showed moderate bilateral optic atrophy. Visual-evoked potential showed an increased P100 latency, more marked in the left eye. Electromyography and nerve-conduction velocity were normal.

Informed consent for participation in this study was obtained from the parents of all individuals involved, in agreement with the Declaration of Helsinki and approved by the ethics committees of the Fondazione IRCCS (Istituto di Ricovero e Cura a Carattere Scientifico) Istituto Neurologico (Milan, Italy).

We first carried out exome-NGS in the index case. The DNA extracted from fibroblasts was processed with the SureSelect Human All Exon 50 Mb kit (Agilent) and subsequently sequenced as 76 base-pair (bp) paired-end runs to an average coverage of 120×, corresponding to 9–12 Gb of sequence data. Read alignment was performed with the use of the Burrows-Wheeler Aligner (version 0.5.8) applied to the human genome assembly hg19. Single-nucleotide variants and small insertions and deletions were detected with SAMtools (version 0.1.7). Given that mitochondrial disorders are rare conditions, we excluded variants with a frequency > 0.2% in “in house” control exomes and public databases. Assuming an autosomal-recessive mode of inheritance, we searched for homozygous or compound-heterozygous variants, which were filtered against (1) variants known to be associated with MRC

defects and (2) novel homozygous or compound-heterozygous variants affecting genes that encode mitochondrial proteins listed in MitoP2 (score > 0.5). This filtering procedure (Table S1 available online) revealed that our index case was compoundheterozygous for mutations in *MTO1*: a maternal c.1858dup (p.Arg620Lysfs*8) and a paternal c.1282G>A (p.Ala428Thr) (Figure 1A). The same mutations were also found in her affected brother.

The frameshift mutation is predicted to introduce a stop codon after an aberrant sequence of seven amino acids (aa) (Figure S1), causing the loss of the C-terminal 73 aa residues (≈10% of the protein size); the missense mutation affects an amino-acid residue, Ala428, which is invariant in all available animal, plant, and yeast species, including *Saccharomyces cerevisiae* (Figures S2A and S2B). In addition, the Ala428Thr change scored very highly for likelihood to be deleterious according to ad-hoc softwares for pathogenicity prediction (deleterious for Polyphen2: p = 0.999; Panther: 0.88041; MutPred: 0.903). The exome variant server (EVS) of the NHLBI GO Exome Sequencing Project reports a frequency of 0.028% (2/7,020) in the American population of European origin for the c.1282G>A change, whereas the c.1858dup change was not present in the database. We also excluded the missense mutation from our exome database, which contains 973 genomes from Europeans (=1,946 alleles), and from a database of 300 alleles from consecutive control DNA samples from subjects originating from northern Italy.

To evaluate a possible influence of the two mutations on the stability of the transcript, we extracted mRNA from mutant fibroblasts of affected individuals 1 and 2 and retrotranscribed it into cDNA. Quantitative real-time PCR showed that the content of mutant *MTO1* transcripts was similar to that of wild-type (WT) control samples (Figure 1B), and sequence analysis revealed the presence of comparable amounts of either mutant transcript (data not shown), indicating no RNA decay.

Next, we analyzed *MTO1* on isolated mitochondria and on total cell lysates obtained from both mutant and control immortalized fibroblasts, using a polyclonal *MTO1* antibody (Proteintech). *MTO1* is predicted by bioinformatic tools (MitoProt, TargetP) to be imported inside mitochondria after the cleavage of a 25-aa-long mitochondrial targeting sequence. We synthesized the polypeptides corresponding to the precursor, the mature WT, and the mature p.Arg620Lysfs*8 truncated *MTO1* species (TNT Transcription-Translation System kit, Promega). After performing SDS-polyacrylamide electrophoresis and electroblotting, we immunovisualized a band reacting with an *MTO1* antibody in mitochondria (Figure 1C) and in fibroblast lysates (Figure S3). This band, which comigrates with a band corresponding to the 74 kDa full-length, mature in-vitro-synthesized *MTO1* polypeptide (NM_012123, NP_036255), was markedly increased in *MTO1*-overexpressing fibroblasts (Figure S3). In mutant mitochondria, the amount of the 74 kDa protein was clearly reduced, whereas an additional band was detected,




Figure 1. MTO1 Mutations

(A) Electropherograms of *MTO1* of Pt2 showing the c.1282G>A (left) and c.1858dup (right), both in heterozygosity.

(B) Real-time PCR on retrotranscribed cDNA from fibroblasts of individuals 1 (P1) and 2 (P2). The amount of *MTO1* transcript (normalized to *GAPDH* levels) is comparable in mutant versus WT control samples (Ct), indicating no mRNA decay. Data are represented as mean \pm SD.

(C) Western-blot analysis of *MTO1*. Top: schematic representation of the precursor WT *MTO1* (isoform a), its mature species after cleavage of a predicted 25 aa mitochondrial targeting sequence in the N terminus, and the mature p.Arg620Lysfs*8 mutant species. Bottom: Western-blot analysis on isolated mitochondria. Retic.: reticulocyte lysate used for in-vitro protein synthesis; Prec.: in-vitro translated 77 kDa *MTO1* precursor protein (green arrowhead); Ct: isolated mitochondria from control fibroblasts; P2: isolated mitochondria from individual 2 fibroblasts; fs*8: in-vitro translated 67 kDa mature protein carrying the truncating p.Arg620Lysfs*8 variant (red arrowhead); Mat.: in-vitro translated 74 kDa WT mature *MTO1* (black arrowhead). A faint crossreacting band is visualized in mt P2 sample (red asterisk), corresponding to the mature p.Arg620Lysfs*8 truncated protein. An unspecific signal is present in mt samples (gray asterisks). The position of the 72 kDa molecular weight marker protein is also indicated. SDHA was used as loading control.

(D) MRR measured in immortalized fibroblasts from Pt 2, in naive condition (P2) or overexpressing *MTO1* (P2+*MTO1*), and in control subjects (Ct1, Ct2). MRR values are expressed as pMolesO₂/min/cells. Data are represented as mean \pm SD. Two-tail, unpaired Student's t test was applied for statistical significance. ***: $p < 0.001$.

with the same electrophoretic mobility of the in-vitro-synthesized mature p.Arg620Lysfs*8 *MTO1* species, predicted to have a molecular weight of \approx 67 kDa. This result suggests that the p.Arg620Lysfs*8 truncated *MTO1* is relatively stable (Figure 1C).

In order to prove the causative role of the *MTO1* variants found in the affected siblings of family 1, we first tested whether the expression of WT *MTO1* cDNA could rescue the biochemical phenotype of mutant cells. Given that the MRC defects in Pt1 and Pt2 fibroblasts were relatively mild and variable, we immortalized the Pt2 fibroblasts using pBABE-puro SV40 and evaluated the oxygen consumption through microscale oxygraphy (Seahorse Bioscience XF-96). This assay, which depends upon and

reflects the cumulative proficiency of the whole set of MRC complexes, is more sensitive than individual assays of each complex.⁸ We demonstrated a clear reduction of the maximal respiration rate (MRR) in immortalized Pt2 cells compared to immortalized control fibroblasts, which returned to normal after transduction with a *MTO1*^{WT}-expressing lentivirus (pLenti6 Gateway Vector kit, Invitrogen) (Figures 1E and S3). This result indicates a pathogenic role of the *MTO1* variants found in Pt2 mutant cells.

Second, we sequenced the exons and exon-intron boundaries of *MTO1* in DNA samples from 17 individuals with early-onset hypertrophic cardiomyopathy, lactic acidosis, and defective MRC activities. We found a single individual, Pt3, homozygous for the c.1282G>A




Figure 2. Respiratory Phenotypes of Yeast Mutant Strains

(A and B) Respiratory activity of yeast *mto1Δ* strains transformed with *MTO1^{WT}* recombinant vector, (empty) vector, and *mto1^{Ala431Thr}* and *mto1^{Pro622*}* recombinant vectors at 28°C (A) and 37°C (B). Respiratory rates were normalized to the WT strain, for which the respiratory rate was 38.2 nmol min⁻¹ mg⁻¹ at 28°C and 28.9 nmol min⁻¹ mg⁻¹ at 37°C. Values are the mean of at least three independent experiments. Two-tail, unpaired t test was applied for statistical significance. *: p < 0.05; **: p < 0.01; ***: p < 0.001. Data are represented as mean ± SD.

(p.Ala428Thr) mutation, identical to that found in the paternal allele of family 1.

In both yeast and humans, *MTO1* encodes the enzyme that catalyzes the 5-carboxymethylaminomethylation (mnm⁵s²U34) of the wobble uridine base in mt-tRNA^{Gln}, mt-tRNA^{Glu}, and mt-tRNA^{Lys}.⁹ This modification is usually coupled to the 2-thiolation of the same uridine moiety, a reaction catalyzed by 2-thiouridylase, encoded by *MTO2* (*TRMU* in humans [MIM 610230]); both these post-transcriptional modifications increase accuracy and efficiency of mtDNA translation.¹⁰ In order to further test the pathogenic role of the *MTO1* mutations, we used the yeast *Saccharomyces cerevisiae*. We first showed that the absence of *MTO1* (*mto1Δ*) was associated with decreased respiration rate in yeast incubated at 28°C (Figure 2A). Second, we demonstrated that this phenotype failed to be corrected by expression of a recombinant yeast *MTO1* cDNA encoding protein variant Pro622*, corresponding to the human Arg620Lysfs*8 change (Figure S2, Table S2). This result suggests that, although present in human mitochondria, the Arg620Lysfs*8 *MTO1* variant is functionally inactive. The respiratory phenotype of the *mto1Δ* strain was only partially corrected by expression of a yeast recombinant *MTO1* encoding protein variant Ala431Thr, corresponding to the human Ala428Thr change (Figure S2, Table S2), whereas the expression of yeast *MTO1^{WT}* led to full recovery (Figure 2A). These results were qualitatively unchanged, but dramatically amplified, in experiments carried out under temperature-induced stress conditions; i.e., at 37°C (Figure 2B). However, neither the growth of *mto1Δ* nor that of *mto1^{Pro622*}* or *mto1^{Ala431Thr}* strains on oxidative carbon sources was significantly impaired. The OXPHOS-negative growth phenotype of *mto1* mutants is in fact contingent on the presence of a C>G transversion at nucleotide 1477 of the 15S rRNA in mtDNA.¹¹ The mutation disrupts the C₁₄₇₇-G₁₅₈₃ base pairing in a functionally relevant hairpin structure, which is part of the decoding site (site A) of the ribo-

some, where the codon-anticodon recognition occurs.¹² This mutation confers resistance to the antibiotic paromomycin (Figure 3) by destabilizing the hairpin and results in a synthetic phenotype with *MTO1* disruption,¹¹ most likely due to impaired interaction between unprocessed *MTO1*-dependent mt-tRNAs with ribosomal site A.¹³

The normal human mitochondrial 12S rRNA contains a hairpin structure that corresponds to the paromomycin-resistant (P^R) variant in yeast, because C₁₄₉₄ and A₁₅₅₅, which are equivalent to yeast C₁₄₇₇ and G₁₅₈₃, cannot form a pair. Incidentally, the well-known pathogenic m.1555A>G mutation of human mtDNA as well as the m.1494C>T can establish a C₁₄₉₄-G₁₅₅₅ pairing or the equivalent U₁₄₉₄-A₁₅₅₅ pairing, respectively, both of which increase the length of the hairpin structure, thus letting paromomycin (and other aminoglycosides) bind to site A (Figure 3).¹⁴ As a consequence, the m.1555A>G and m.1494C>T both confer aminoglycoside susceptibility to human mtDNA, being associated with a specific phenotype, aminoglycoside-induced nonsyndromic deafness (MIM 580000).^{15,16}

Given that human WT 12S RNA site A is structurally similar to the yeast P^R variant of the 15S RNA site A (Figure 3), we extended our complementation analysis to a m.1477C>G mutant P^R yeast strain.

We showed that, in contrast to the *mto1Δ* paromomycin-sensitive (P^S) strain, the *mto1Δ* P^R strain was unable to grow on oxidative carbon sources such as glycerol (Figure 4A). The oxidative growth remained abolished with the expression of a cDNA encoding Mto1^{Pro622*}, clearly reduced with the expression of a cDNA encoding Mto1^{Ala431Thr}, and fully restored with the expression of a cDNA encoding *MTO1^{WT}* (Figure 4A).

Likewise, the respiration rate, which was nearly abolished in the *mto1Δ* P^R strain, was not corrected by transformation with the Mto1^{Pro622*}-encoding cDNA and only partially corrected by the Mto1^{Ala431Thr}-encoding cDNA, in contrast to the full recovery obtained by expressing a *MTO1^{WT}* cDNA (Figure 4B). We observed no difference between *MTO1^{WT}* and *mto1* mutant strains in the frequency of “petite” colonies; i.e., respiration-defective




Figure 3. A-Site Structures of Yeast 15S and Human 12S rRNAs

Secondary structure of site A of the WT yeast strain 15S rRNA, of the P^R yeast strain 15S rRNA, of the WT human 12S rRNA, and of the mutant human 12S rRNA—the last two carrying either the 1555G or the 1494T mtDNA mutation, both associated with P^S. The pairing of 1477–1583 nucleotides in WT yeast rRNA corresponds to that of 1494–1555 nucleotides in mutant human rRNA and confers aminoglycoside susceptibility.

clones caused by large deletions or loss of mtDNA (data not shown), which indicates that mutations in *MTO1* did not affect mtDNA stability.

Analysis in yeast clearly shows that while both mutations are detrimental for respiratory activity, the deleterious effects of the Pro622* protein variant is more severe than the Ala431Thr replacement. These results are concordant with the clinical phenotype associated with the equivalent mutations in humans: the third affected individual, homozygous for the *MTO1* mutation encoding the Ala428Thr protein variant, equivalent to the yeast Ala431Thr, is now 19 years old, and in relatively well-compensated condition, whereas individuals 1 and 2, who were compound heterozygous for the *MTO1* mutations encoding the Ala428Thr and Arg620Lysfs*8 mutations, the latter being equivalent to the yeast Pro622*, died a few days after birth of intractable congestive heart failure and severe lactic acidosis.

MTO1 encodes a FAD-containing enzyme involved in posttranscriptional modification of specific mt-tRNAs, thus contributing to the optimization of mtDNA-dependent protein synthesis. However, similar to a recent report on the effects on in-vivo mtDNA translation of *TRMU* (*MTO2*) mutations,¹⁷ we failed to show consistent alterations of mtDNA-dependent protein synthesis in Pt2 mutant fibroblasts assayed in standard conditions¹⁸ (Figure S4). Hence, we evaluated the effect on mtDNA translation of the expression of cDNAs encoding the Mto1^{Pro622*} and Mto1^{Ala431Thr} variants, versus MTO1^{WT}, in the highly sensitive *mto1Δ* P^R yeast model.¹⁹ Interestingly, the mtDNA protein synthesis in the *mto1Δ* strain expressing a cDNA encoding Mto1^{Pro622*} was markedly reduced, particularly for cytochrome *c* oxidase (Cox) subunits 1 and 2 and for cytochrome *b*, similar to, albeit

less than, the null *mto1Δ* strain. The mtDNA translation pattern in the *mto1Δ* strain expressing a cDNA encoding Mto1^{Ala431Thr} was similar to that of the MTO1^{WT} strain, although some bands, such as those corresponding to the Var1 and adenosine triphosphatase (ATPase) 6 polypeptides, were slightly reduced in the mutant versus WT strains (Figure 5). As expected, these results confirm that the effects of the Mto1^{Pro622*} truncating mutation are more deleterious on mtDNA translation than those of the Mto1^{Ala431Thr} missense mutation, in agreement with the results of the respiratory and oxidative-growth phenotypes in yeast and of the greater severity of the clinical phenotype in individuals 1 and 2 versus that of individual 3.

The function of MTO1 could explain the variability of the biochemical defects, ranging from isolated CI deficiency, as in Pt2 fibroblasts, to combined CI-CIV deficiency in Pt2 and Pt3 skeletal muscle, or to combined CIII-CIV deficiency in Pt1 fibroblasts. Among the 13 mtDNA-encoded proteins, seven are subunits of CI, three of CIV, two of CV, and one of CIII. This gene distribution can explain why mtDNA translation defects such as those associated with mutations of *MTO1* can predominantly impair the activity of CI, but also that of CIII and CIV. The two mtDNA-encoded subunits of CV are part of the F0 component of this complex, the function of which is not directly measured by the standard CV assay that is based on ATP-hydrolysis, a function carried out by the F1 component of CV. This could explain, at least in part, why CV activity was essentially normal in *MTO1* mutant samples.

The presence of a FAD moiety in MTO1 opens the possibility that, as observed for other mitochondrial flavo-enzymes,^{1,3,20} riboflavin supplementation may be beneficial for correction, at least in part, of the biochemical




Figure 4. P^R and P^S Yeast Phenotypes

(A) Spot assay of *mto1Δ* P^R and P^S strains, transformed with *MTO1*^{WT} recombinant vector, (empty) vector, and *mto1*^{Ala431Thr} and *mto1*^{Pro622*} recombinant vectors. The assay was performed by spotting decreasing concentrations of yeast cells (10⁵, 10⁴, 10³, and 10²) on a medium supplemented with either 2% glucose (upper panel) or 2% glycerol (lower panel). See text for details.

(B) Respiratory activity of yeast *MTO1*^{WT} and mutant P^R strains at 28°C. Respiratory rates were normalized to the WT strain, for which the respiratory rate was 26.6 nmol min⁻¹ mg⁻¹. Values are the mean of at least four independent experiments. Two-tail, unpaired t test was applied for statistical significance. *: p < 0.05; **: p < 0.01; ***: p < 0.001.

Data are represented as mean ± SD.

defect and improvement of the clinical course. However, we observed neither correction of MRC biochemical activities (Table 1) nor improvement of oxygen consumption (data not shown) by growing Pt1 and Pt2 mutant fibroblasts in 5.3 μM riboflavin for 1 week. Likewise, addition of different amounts of riboflavin (0.53, 2.6, 5.3, 13.3, and 26.6 μM) to a glycerol medium had no effect on either growth or respiration of *mto1* mutant yeast strains (data not shown). These results indicate that riboflavin supplementation is ineffective, possibly because the truncating mutation is too drastic and the missense mutation does not affect the N-terminal, FAD-binding domain of the protein.²¹

An additional source of complexity stems from the existence of transcript variants encoding at least three different *MTO1* isoforms. Although isoform a is prevalent, being in fact the only one that we could detect in fibroblasts, the presence of isoforms b (NM_133645, NP_598400) and c (NM_001123226, NP_001116698) is also predicted, each retaining a different extra-exon resulting in protein

sequences longer than those of isoform a.²² The existence and functional significance of these longer variants are presently unknown. Notably, both mutations found in this study affect the protein sequence common to all three isoforms, predicting overall impairment of the *MTO1* function.

MTO1 and *MTO2* (TRMU) take part in the same pathway involved in posttranscriptional modification of specific mt-tRNAs.¹⁰ Interestingly, specific *TRMU* mutations cause severe and sometimes fatal liver failure (MIM 613070),²³ and other mutations in the same gene have been associated with reversible mitochondrial myopathy.²⁴ Here we report mutations of *MTO1* associated with impairment of yet another target organ, the heart, the severity of which seems to depend on the potential deleteriousness of the mutations. The mechanisms underlying such diverse tissue and organ specificity in the same enzyme or in the same enzymatic pathway is a challenge for future work in this rapidly expanding field of mitochondrial medicine.




Figure 5. In-Vivo Mitochondrial Translation of P^R *mto1*Δ Strain Transformed with WT or Mutant *MTO1* Alleles

Mitochondrial gene products were labeled with [³⁵S] methionine in whole cells at 30°C in the presence of cycloheximide for 7 min.¹⁹ Equivalent amounts of total cellular proteins were separated by SDS-PAGE on a 17.5% polyacrylamide gel, transferred to a nitrocellulose membrane, and exposed to X-ray film. The *mto1*Δ strain transformed with the empty vector (vector) contained 40% of petite cells, thus reducing the overall signal. Cox: cytochrome *c* oxidase; Cob: cytochrome *b*; Atp: ATP synthase; Var1: small mitochondrial ribosome subunit. In the *mto1*^{Pro622*} strain, several bands, particularly Cox1, Cox2, and Cob, are virtually missing, and the overall pattern is similar to that of the (empty) vector. In the *mto1*^{Ala431Thr}, the intensity of some bands, including Var1 and Atp6, is slightly reduced compared to the *MTO1*^{WT} strain, but the two patterns are similar, suggesting mild impairment.

Supplemental Data

Supplemental Data include four figures and two tables and can be found with this article online at <http://www.cell.com/AJHG/>.

Acknowledgments

We thank Alexander Tzagoloff for the generous gift of the P^R yeast strain. We are grateful to Erika Fernandez-Vizarrá for help with the in vivo translation assay, to Alessia Nasca for the screening of the Italian DNA control samples, and to Ilaria D'Amato for technical support with microscale oxygraphy. This work was supported by the Pierfranco and Luisa Mariani Foundation of Italy; Fondazione Telethon grants GGP11011 and GPP10005; CARIPLO grant 2011/0526; the Italian Association of Mitochondrial Disease Patients and Families (Mitocon); the Helmholtz Alliance for Mental Health in an Ageing Society (HA-215) and the German Federal Ministry of

Education and Research (BMBF)-funded Systems Biology of Metabotypes grant (SysMBo 0315494A); the German Network for Mitochondrial Disorders (mitoNET 01GM0867 and 01GM0862); and E-Rare grant GenoMit JTC2011.

Received: January 26, 2012

Revised: March 6, 2012

Accepted: April 12, 2012

Published online: May 17, 2012

Web Resources

The URLs for data presented herein are as follows:

Exome Variant Server (EVS), <http://evs.gs.washington.edu/EVS>

MitoP2, <http://www.mitop.de>

MitoProt, <http://ihg2.helmholtz-muenchen.de/ihg/mitoprot.html>

MutPred, <http://mutpred.mutdb.org>

Online Mendelian Inheritance in Man (OMIM), <http://www.omim.org>

Panther, <http://www.pantherdb.org>

Polyphen2, <http://genetics.bwh.harvard.edu/pph2>

TargetP, <http://www.cbs.dtu.dk/services/TargetP>

References

- Haack, T.B., Danhauser, K., Haberberger, B., Hoser, J., Strecker, V., Boehm, D., Uziel, G., Lamantea, E., Invernizzi, F., Poulton, J., et al. (2010). Exome sequencing identifies ACAD9 mutations as a cause of complex I deficiency. *Nat. Genet.* **42**, 1131–1134.
- Nouws, J., Nijtmans, L., Houten, S.M., van den Brand, M., Huynen, M., Venselaar, H., Hoefs, S., Gloerich, J., Kronick, J., Hutchin, T., et al. (2010). Acyl-CoA dehydrogenase 9 is required for the biogenesis of oxidative phosphorylation complex I. *Cell Metab.* **12**, 283–294.
- Gerards, M., van den Bosch, B.J., Danhauser, K., Serre, V., van Weeghel, M., Wanders, R.J., Nicolaes, G.A., Sluiter, W., Schoonderwoerd, K., Scholte, H.R., et al. (2011). Riboflavin-responsive oxidative phosphorylation complex I deficiency caused by defective ACAD9: new function for an old gene. *Brain* **134**, 210–219.
- Mayr, J.A., Haack, T.B., Graf, E., Zimmermann, F.A., Wieland, T., Haberberger, B., Superti-Furga, A., Kirschner, J., Steinmann, B., Baumgartner, M.R., et al. (2012). Lack of the mitochondrial protein acylglycerol kinase causes Sengers syndrome. *Am. J. Hum. Genet.* **90**, 314–320.
- Cížková, A., Stránecký, V., Mayr, J.A., Tesarová, M., Havlíčková, V., Paul, J., Ivánek, R., Kuss, A.W., Hansíková, H., Kaplanová, V., et al. (2008). TMEM70 mutations cause isolated ATP synthase deficiency and neonatal mitochondrial encephalomyopathy. *Nat. Genet.* **40**, 1288–1290.
- Uziel, G., Ghezzi, D., and Zeviani, M. (2011). Infantile mitochondrial encephalopathy. *Semin. Fetal Neonatal Med.* **16**, 205–215.
- Burlina, A.B., Milanese, O., Biban, P., Bordugo, A., Garavaglia, B., Zacchello, F., and DiMauro, S. (1993). Beneficial effect of sodium dichloroacetate in muscle cytochrome C oxidase deficiency. *Eur. J. Pediatr.* **152**, 537.
- Invernizzi, F., D'Amato, I., Jensen, P.B., Ravaglia, S., Zeviani, M., and Tiranti, V. (2012). Microscale oxygraphy reveals

- OXPHOS impairment in MRC mutant cells. *Mitochondrion* 12, 328–335.
9. Wang, X., Yan, Q., and Guan, M.X. (2010). Combination of the loss of cmnm5U34 with the lack of s2U34 modifications of tRNALys, tRNAGlu, and tRNAGln altered mitochondrial biogenesis and respiration. *J. Mol. Biol.* 395, 1038–1048.
 10. Umeda, N., Suzuki, T., Yukawa, M., Ohya, Y., Shindo, H., Watanabe, K., and Suzuki, T. (2005). Mitochondria-specific RNA-modifying enzymes responsible for the biosynthesis of the wobble base in mitochondrial tRNAs. Implications for the molecular pathogenesis of human mitochondrial diseases. *J. Biol. Chem.* 280, 1613–1624.
 11. Colby, G., Wu, M., and Tzagoloff, A. (1998). MTO1 codes for a mitochondrial protein required for respiration in paromomycin-resistant mutants of *Saccharomyces cerevisiae*. *J. Biol. Chem.* 273, 27945–27952.
 12. Yan, Q., Li, X., Faye, G., and Guan, M.X. (2005). Mutations in MTO2 related to tRNA modification impair mitochondrial gene expression and protein synthesis in the presence of a paromomycin resistance mutation in mitochondrial 15 S rRNA. *J. Biol. Chem.* 280, 29151–29157.
 13. Wang, X., Yan, Q., and Guan, M.X. (2009). Mutation in MTO1 involved in tRNA modification impairs mitochondrial RNA metabolism in the yeast *Saccharomyces cerevisiae*. *Mitochondrion* 9, 180–185.
 14. Qian, Y., and Guan, M.X. (2009). Interaction of aminoglycosides with human mitochondrial 12S rRNA carrying the deafness-associated mutation. *Antimicrob. Agents Chemother.* 53, 4612–4618.
 15. Prezant, T.R., Agapian, J.V., Bohlman, M.C., Bu, X., Oztas, S., Qiu, W.Q., Arnos, K.S., Cortopassi, G.A., Jaber, L., Rotter, J.I., et al. (1993). Mitochondrial ribosomal RNA mutation associated with both antibiotic-induced and non-syndromic deafness. *Nat. Genet.* 4, 289–294.
 16. Zhao, H., Li, R., Wang, Q., Yan, Q., Deng, J.H., Han, D., Bai, Y., Young, W.Y., and Guan, M.X. (2004). Maternally inherited aminoglycoside-induced and nonsyndromic deafness is associated with the novel C1494T mutation in the mitochondrial 12S rRNA gene in a large Chinese family. *Am. J. Hum. Genet.* 74, 139–152.
 17. Sasarman, F., Antonicka, H., Horvath, R., and Shoubridge, E.A. (2011). The 2-thiouridylase function of the human MTU1 (TRMU) enzyme is dispensable for mitochondrial translation. *Hum. Mol. Genet.* 20, 4634–4643.
 18. Fernández-Silva, P., Acín-Pérez, R., Fernández-Vizarra, E., Pérez-Martos, A., and Enriquez, J.A. (2007). In vivo and in organello analyses of mitochondrial translation. *Methods Cell Biol.* 80, 571–588.
 19. Barrientos, A., Korr, D., and Tzagoloff, A. (2002). Shy1p is necessary for full expression of mitochondrial COX1 in the yeast model of Leigh's syndrome. *EMBO J.* 21, 43–52.
 20. Ghezzi, D., Sevrioukova, I., Invernizzi, F., Lamperti, C., Mora, M., D'Adamo, P., Novara, F., Zuffardi, O., Uziel, G., and Zeviani, M. (2010). Severe X-linked mitochondrial encephalomyopathy associated with a mutation in apoptosis-inducing factor. *Am. J. Hum. Genet.* 86, 639–649.
 21. Shi, R., Villarroya, M., Ruiz-Partida, R., Li, Y., Proteau, A., Prado, S., Moukadiri, I., Benítez-Páez, A., Lomas, R., Wagner, J., et al. (2009). Structure-function analysis of *Escherichia coli* MnmG (GidA), a highly conserved tRNA-modifying enzyme. *J. Bacteriol.* 191, 7614–7619.
 22. Li, X., Li, R., Lin, X., and Guan, M.X. (2002). Isolation and characterization of the putative nuclear modifier gene MTO1 involved in the pathogenesis of deafness-associated mitochondrial 12 S rRNA A1555G mutation. *J. Biol. Chem.* 277, 27256–27264.
 23. Zeharia, A., Shaag, A., Pappo, O., Mager-Heckel, A.M., Saada, A., Beinat, M., Karicheva, O., Mandel, H., Ofek, N., Segel, R., et al. (2009). Acute infantile liver failure due to mutations in the TRMU gene. *Am. J. Hum. Genet.* 85, 401–407.
 24. Uusimaa, J., Jungbluth, H., Fratter, C., Crisponi, G., Feng, L., Zeviani, M., Hughes, I., Treacy, E.P., Birks, J., Brown, G.K., et al. (2011). Reversible infantile respiratory chain deficiency is a unique, genetically heterogeneous mitochondrial disease. *J. Med. Genet.* 48, 660–668.